RU2012116880A - Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов - Google Patents
Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов Download PDFInfo
- Publication number
- RU2012116880A RU2012116880A RU2012116880/15A RU2012116880A RU2012116880A RU 2012116880 A RU2012116880 A RU 2012116880A RU 2012116880/15 A RU2012116880/15 A RU 2012116880/15A RU 2012116880 A RU2012116880 A RU 2012116880A RU 2012116880 A RU2012116880 A RU 2012116880A
- Authority
- RU
- Russia
- Prior art keywords
- alpha
- ethylene oxide
- nanoparticle
- hydroxyphosphonate
- nanoparticles
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract 18
- 239000002872 contrast media Substances 0.000 title claims abstract 4
- 239000002253 acid Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 12
- 229920000642 polymer Polymers 0.000 claims abstract 12
- 238000000034 method Methods 0.000 claims abstract 11
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims abstract 8
- 125000006850 spacer group Chemical group 0.000 claims abstract 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract 4
- 238000002059 diagnostic imaging Methods 0.000 claims abstract 4
- 238000002595 magnetic resonance imaging Methods 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 238000002347 injection Methods 0.000 claims abstract 2
- 239000007924 injection Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 239000002616 MRI contrast agent Substances 0.000 abstract 1
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1842—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a phosphate or a phosphonate, not being a phospholipid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
- A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
- A61K49/186—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA the organic macromolecular compound being polyethyleneglycol [PEG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Nanotechnology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Radiology & Medical Imaging (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/609,799 US9205155B2 (en) | 2009-10-30 | 2009-10-30 | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents |
| US12/609,799 | 2009-10-30 | ||
| PCT/EP2010/066429 WO2011051422A2 (en) | 2009-10-30 | 2010-10-29 | Treating water insoluble nanoparticles with hydrophilic alpha-hydroxyphosphonic acid conjugates, the so modified nanoparticles and their use as contrast agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012116880A true RU2012116880A (ru) | 2013-12-10 |
Family
ID=43480950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012116880/15A RU2012116880A (ru) | 2009-10-30 | 2010-10-29 | Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9205155B2 (enExample) |
| EP (1) | EP2493512B1 (enExample) |
| JP (1) | JP5997609B2 (enExample) |
| KR (1) | KR20120101362A (enExample) |
| CN (1) | CN102639153B (enExample) |
| AU (1) | AU2010311437A1 (enExample) |
| BR (1) | BR112012010113A2 (enExample) |
| CA (1) | CA2777871A1 (enExample) |
| ES (1) | ES2720152T3 (enExample) |
| IN (1) | IN2012DN02804A (enExample) |
| MX (1) | MX2012005022A (enExample) |
| RU (1) | RU2012116880A (enExample) |
| WO (1) | WO2011051422A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767430C2 (ru) * | 2017-06-28 | 2022-03-17 | Рикен | Наночастица, содержащее ее контрастное вещество для магнитно-резонансной томографии и лигандное соединение |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8986836B2 (en) * | 2009-03-19 | 2015-03-24 | Ohio University | Microspheres and their methods of preparation |
| US8920681B2 (en) | 2009-12-30 | 2014-12-30 | Korea University Research And Business Foundation | Electrically conductive polymers with enhanced conductivity |
| US8889103B2 (en) | 2010-12-15 | 2014-11-18 | General Electric Company | Diagnostic agent composition and associated methods thereof |
| RU2013125324A (ru) * | 2010-12-15 | 2015-01-20 | Дженерал Электрик Компани | Композиция наночастиц и связанные с ней способы |
| US8895068B2 (en) | 2010-12-15 | 2014-11-25 | General Electric Company | Nanoparticle composition and associated methods thereof |
| US9474810B2 (en) * | 2012-03-02 | 2016-10-25 | General Electric Company | Superparamagnetic nanoparticles with PEG substituted α-hydroxy phosphonate shells |
| US9251937B2 (en) * | 2012-06-29 | 2016-02-02 | General Electric Company | Heat stable nanoparticle preparations and associated methods thereof |
| US20190001001A1 (en) * | 2017-07-03 | 2019-01-03 | General Electric Company | Drug design for application-dependent payload, controlled pharmacokinetic distribution, and renal clearance |
| US11577977B2 (en) * | 2017-09-26 | 2023-02-14 | The Board Of Trustees Of The University Of Arkansas | Composite zero valent iron nanoparticles and applications thereof |
| CN110734460B (zh) * | 2019-10-22 | 2022-03-29 | 华南师范大学 | 一类磺酸-膦酸配体的制备及其用途 |
| CN118748269B (zh) * | 2024-08-05 | 2025-10-31 | 瑞固(衢州)新材料科技有限公司 | 一种硫化物固态电解质及其制备方法与电池 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5651493A (en) | 1979-10-02 | 1981-05-09 | Yoshitomi Pharmaceut Ind Ltd | Diphosphoglycerol and its preparation |
| JPS6043217A (ja) | 1983-08-19 | 1985-03-07 | Toshiba Corp | 磁気記録媒体 |
| DE3343586A1 (de) | 1983-11-29 | 1985-06-05 | Herbert Dr. 1000 Berlin Pilgrimm | Verfahren zur entkeimung eines mediums und vorrichtung zur durchfuehrung |
| DE3440190A1 (de) | 1984-11-01 | 1986-05-15 | Michel-Kim, Herwig, 1000 Berlin | Verfahren und vorrichtung zur erzeugung von stickstoffduenger und stickstoffangereicherter biomasse aus luft |
| DE3443810A1 (de) | 1984-11-28 | 1986-05-28 | Herbert Dr. 1000 Berlin Pilgrimm | Verfahren zur entkeimung eines mediums |
| DE3624626A1 (de) | 1986-07-18 | 1988-01-28 | Pilgrimm Herbert | Verfahren zur abtrennung von stoffen aus einem stoffgemisch unter verwendung von magnetischen fluessigkeiten |
| DE3709852A1 (de) | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Stabile magnetische fluessigkeitszusammensetzungen und verfahren zu ihrer herstellung und ihre verwendung |
| DE3709851A1 (de) | 1987-03-24 | 1988-10-06 | Silica Gel Gmbh Adsorptions Te | Nmr-diagnostische fluessigkeitszusammensetzungen |
| DE4309333A1 (de) | 1993-03-17 | 1994-09-22 | Silica Gel Gmbh | Superparamagnetische Teilchen, Verfahren zu ihrer Herstellung und Verwendung derselben |
| JPH08508721A (ja) | 1993-03-17 | 1996-09-17 | シリカゲル ゲス．エム．ビー．エイチ | 超常磁性粒子、その製法及びその用途 |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| ATE191086T1 (de) | 1994-07-27 | 2000-04-15 | Pilgrimm Herbert | Superparamagnetische teilchen, verfahren zur herstellung und deren verwendung |
| DE19612001A1 (de) | 1996-03-18 | 1997-09-25 | Silica Gel Gmbh Adsorptions Te | Superparamagnetische Teilchen mit vergrößerter R¶1¶-Relaxivität, Verfahren zur Herstellung und deren Verwendung |
| DE19726282A1 (de) | 1997-06-20 | 1998-12-24 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern |
| DE10016559A1 (de) | 2000-04-03 | 2001-10-18 | Eucro Europe Contract Res Gmbh | System für den Transport von Aktivstoffen in einem biologischen System |
| EP1425245B1 (en) | 2001-08-16 | 2010-06-30 | Essilor International Compagnie Generale D'optique | Method for preparing stable dispersions of metallic nanoparticles, stable dispersions obtained therefrom and coating compositions containing them |
| DE10222481A1 (de) | 2002-05-22 | 2003-12-04 | Eucro Europe Contract Res Gmbh | Kontrastmittel für die Verwendung in bildgebenden Verfahren |
| US6797380B2 (en) | 2002-07-31 | 2004-09-28 | General Electric Company | Nanoparticle having an inorganic core |
| DE10297833D2 (de) | 2002-10-09 | 2005-09-01 | Ferropharm Gmbh Forschungslabo | Stabilisierte superparamagnetische Teilchen |
| US7560160B2 (en) | 2002-11-25 | 2009-07-14 | Materials Modification, Inc. | Multifunctional particulate material, fluid, and composition |
| FR2848850B1 (fr) | 2002-12-20 | 2005-06-24 | Guerbet Sa | Nouvelles compositions de particules magnetiques recouvertes de derives gem-bisphosphonates. |
| US20040161435A1 (en) | 2003-02-14 | 2004-08-19 | Gupta Shyam K. | Skin Firming Anti-Aging Cosmetic Mask Compositions |
| DE10323816A1 (de) | 2003-05-23 | 2004-12-09 | Basf Ag | Verfahren zur Herstellung von Mischoxiden mit mittleren Durchmessern kleiner als 10 Nanometer |
| US20060018835A1 (en) | 2004-04-02 | 2006-01-26 | General Electric Company | Nanoparticles with inorganic core and methods of using them |
| CN100334166C (zh) | 2005-01-26 | 2007-08-29 | 上海大学 | 一种纳米碳酸钙的改性方法 |
| US8084275B2 (en) | 2005-02-08 | 2011-12-27 | Fujifilm Corporation | Magnetic composite body, production method thereof, method for removing substance with mannose on its surface, and method for concentrating substance with mannose on its surface |
| KR100746312B1 (ko) | 2005-03-14 | 2007-08-03 | 한국화학연구원 | 수용성 산화철 나노 입자 및 이의 제조방법 |
| KR20080040632A (ko) | 2005-05-12 | 2008-05-08 | 조지아 테크 리서치 코포레이션 | 코팅된 금속 산화물 나노입자 및 그의 제조방법 |
| US7767736B2 (en) | 2005-12-05 | 2010-08-03 | 3M Innovative Properties Company | Flame retardant polymer composition |
| DE102005059751A1 (de) | 2005-12-09 | 2007-06-14 | Ferropharm Gmbh Forschungslabor | Wässrige Dispersion von superparamagnetischen Eindomänenteilchen, deren Herstellung und Verwendung zur Diagnose und Therapie |
| ITFI20060006A1 (it) | 2006-01-04 | 2007-07-05 | Colorobbia Italiana Spa | Nanoparticelle funzionalizzate, loro produzione ed uso |
| DE102006007888A1 (de) | 2006-02-21 | 2007-08-23 | Degussa Gmbh | Aluminiumoxid enthaltende Dispersion, Zubereitung enthaltend diese Dispersion und ein Melaminharz und mittels dieser Zubereitung hergestelles gehärtetes Produkt |
| WO2007133801A2 (en) | 2006-05-15 | 2007-11-22 | Dmitri B Kirpotin | Magnetic microparticles comprising organic substances |
| FR2904784B1 (fr) * | 2006-08-10 | 2010-09-03 | Surfactis Technologies | Procede de recouvrement de surfaces metalliques et minerales par de monocouches autoassemblees de composes bisphosphoniques et leurs utilisations |
| US20080299046A1 (en) | 2006-10-16 | 2008-12-04 | The Trustees Of Columbia University In The City Of New York | Methods for controlling surface functionality of metal oxide nanoparticles, metal oxide nanoparticles having controlled functionality, and uses thereof |
| EP2152320A2 (en) | 2007-04-30 | 2010-02-17 | Intezyne Technologies Incorporated | Encapsulated contrast agents |
| US9072789B2 (en) | 2007-07-20 | 2015-07-07 | The Trustees Of Princeton University | Nano-particle surface modification |
| SG150405A1 (en) | 2007-08-29 | 2009-03-30 | Agency Science Tech & Res | Method of coating a particle |
| FR2921838A1 (fr) | 2007-10-05 | 2009-04-10 | Guerbet Sa | Nouveau procede de preparation de nanoparticules recouvertes d'une couche stabilisatrice gem-bisphosphonate couplee a des ligands de biodistribution hydrophile |
| KR20090038337A (ko) | 2007-10-15 | 2009-04-20 | 재단법인서울대학교산학협력재단 | 무기계 나노입자를 수계 매질에 분산시키는 생체적합성분산 안정화제 |
| JP2011519342A (ja) | 2007-12-13 | 2011-07-07 | アドゥロ バイオテック | リガンド結合温熱療法サセプタおよびその作成方法 |
| US20090226376A1 (en) * | 2008-03-05 | 2009-09-10 | General Electric Company | Novel Mixed Ligand Core/Shell Iron Oxide Nanoparticles for Inflammation Imaging |
| US8173198B2 (en) | 2008-07-23 | 2012-05-08 | Life Technologies Corporation | Deposition of metal oxides onto surfaces as an immobilization vehicle for carboxylated or phophated particles or polymers |
| US20100166664A1 (en) | 2008-12-29 | 2010-07-01 | General Electric Company | Nanoparticle contrast agents for diagnostic imaging |
-
2009
- 2009-10-30 US US12/609,799 patent/US9205155B2/en active Active
-
2010
- 2010-10-29 AU AU2010311437A patent/AU2010311437A1/en not_active Abandoned
- 2010-10-29 RU RU2012116880/15A patent/RU2012116880A/ru not_active Application Discontinuation
- 2010-10-29 ES ES10771742T patent/ES2720152T3/es active Active
- 2010-10-29 KR KR1020127010759A patent/KR20120101362A/ko not_active Withdrawn
- 2010-10-29 CA CA2777871A patent/CA2777871A1/en not_active Abandoned
- 2010-10-29 EP EP10771742.3A patent/EP2493512B1/en active Active
- 2010-10-29 BR BR112012010113A patent/BR112012010113A2/pt not_active IP Right Cessation
- 2010-10-29 IN IN2804DEN2012 patent/IN2012DN02804A/en unknown
- 2010-10-29 CN CN201080049469.4A patent/CN102639153B/zh active Active
- 2010-10-29 JP JP2012535840A patent/JP5997609B2/ja active Active
- 2010-10-29 WO PCT/EP2010/066429 patent/WO2011051422A2/en not_active Ceased
- 2010-10-29 MX MX2012005022A patent/MX2012005022A/es not_active Application Discontinuation
-
2015
- 2015-10-21 US US14/919,077 patent/US9827335B2/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2767430C2 (ru) * | 2017-06-28 | 2022-03-17 | Рикен | Наночастица, содержащее ее контрастное вещество для магнитно-резонансной томографии и лигандное соединение |
| US11389550B2 (en) | 2017-06-28 | 2022-07-19 | Riken | Nanoparticle, contrast agent for magnetic resonance imaging containing same, and ligand compound |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012005022A (es) | 2012-06-08 |
| US20160038617A1 (en) | 2016-02-11 |
| CN102639153B (zh) | 2017-02-22 |
| EP2493512A2 (en) | 2012-09-05 |
| ES2720152T3 (es) | 2019-07-18 |
| AU2010311437A1 (en) | 2012-04-12 |
| IN2012DN02804A (enExample) | 2015-07-24 |
| US9205155B2 (en) | 2015-12-08 |
| US20110104072A1 (en) | 2011-05-05 |
| JP5997609B2 (ja) | 2016-09-28 |
| EP2493512B1 (en) | 2019-01-23 |
| CN102639153A (zh) | 2012-08-15 |
| BR112012010113A2 (pt) | 2019-09-24 |
| CA2777871A1 (en) | 2011-05-05 |
| US9827335B2 (en) | 2017-11-28 |
| JP2013509381A (ja) | 2013-03-14 |
| WO2011051422A3 (en) | 2011-07-21 |
| KR20120101362A (ko) | 2012-09-13 |
| WO2011051422A2 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012116880A (ru) | Обработка нерастворимых в воде наночастиц гидрофильными конъюгатами альфа-гидроксифосфоновой кислоты, модифицированные таким образом наночастицы и их применение в качестве контрастных агентов | |
| Zelepukin et al. | Fast processes of nanoparticle blood clearance: Comprehensive study | |
| Kim et al. | A cancer-recognizable MRI contrast agents using pH-responsive polymeric micelle | |
| Jalili et al. | Injectable nanoengineered stimuli-responsive hydrogels for on-demand and localized therapeutic delivery | |
| Park et al. | Multi-modal transfection agent based on monodisperse magnetic nanoparticles for stem cell gene delivery and tracking | |
| CN104826139B (zh) | 一种rgd多肽靶向的超小四氧化三铁mri阳性纳米探针的制备方法 | |
| Lin et al. | Carboxymethyl chitosan-assisted MnOx nanoparticles: Synthesis, characterization, detection and cartilage repair in early osteoarthritis | |
| ES2787502T3 (es) | Polímero biocompatible y nanopartícula magnética con biocompatibilidad | |
| JP2013509381A5 (enExample) | ||
| CN104399092A (zh) | 一种rgd修饰的超小型超顺磁氧化铁纳米颗粒的制备方法 | |
| ES2718424T3 (es) | Un procedimiento para preparar nanopartículas poliméricas monocatenarias dispersables en agua | |
| CN104784711B (zh) | 透明质酸稳定的高弛豫率氧化钆磁共振纳米探针 | |
| Meng et al. | Matrix metalloproteinase-initiated aggregation of melanin nanoparticles as highly efficient contrast agent for enhanced tumor accumulation and dual-modal imaging | |
| Li et al. | A pH-responsive magnetic resonance tuning probe for precise imaging of bacterial infection in vivo | |
| Wu et al. | Multifunctional nanostructures for tumor-targeted molecular imaging and photodynamic therapy | |
| CN105327367B (zh) | 一种成像剂、制备方法和用途 | |
| CN113616815B (zh) | pH响应的T1/T2切换型MRI造影剂及其制备方法与应用 | |
| CN103417992A (zh) | 一种四氧化三铁纳米颗粒靶向mri造影剂的制备方法 | |
| CN107349434A (zh) | 一种超支化聚合物及其制备方法和应用 | |
| CN110496231A (zh) | 一种含有聚多巴氨基酸螯合三价铁离子的两亲性聚合物纳米胶束及应用 | |
| Zhang et al. | Functionalized magnetic nanochains with enhanced MR imaging: a novel nanosystem for targeting and inhibition of early glioma | |
| KR101541969B1 (ko) | 단백질 전달용 나노 복합체 및 이의 제조방법 | |
| CN103432585A (zh) | 叶酸受体α亚型高效介导的靶向标记系统 | |
| Li et al. | Nile red loaded PLGA nanoparticles surface modified with Gd-DTPA for potential dual-modal imaging | |
| Wang et al. | Insights into Non‐Metallic Magnetic Resonance Imaging Contrast Agents: Advances and Perspectives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160627 |